Skip to content
i2E
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
Search

State support seeds Altheus

Get in Touch

By Scott Meacham

Copyright © The Oklahoma Publishing Company

Altheus Therapeutics Inc. is an Oklahoma homegrown example of a startup bioscience company doing drug commercialization right.

The company shows what can come about when the Oklahoma Center for the Advancement of Science and Technology, the University of Oklahoma, the state’s bioscience community, angel investors, and i2E combine resources, dollars, and expertise to help a bioscience company with a great technology beat the odds.

Altheus provides novel front-line therapies for treating ulcerative colitis and potentially other inflammatory bowel diseases. The causes of these autoimmune conditions are not known. There is no known cure. The symptoms are chronic and typically require a lifetime of care.

Altheus was founded just six years ago with technology licensed from OU and $3.6 million in venture capital from the Oklahoma Seed Capital Fund and other investors.

Six years can be multiple lifetimes for an iPhone app, but in the world of drug development, it can take many more than half-a-dozen years before a startup even has a drug to test.

Today Altheus has raised nearly $15 million through equity and grants, and is in the final stages of a 120-patient FDA Phase 2 clinical trial. Once the trial concludes and the analysis is complete, Altheus will be on the path (in months not years) to progress to Phase 3, a larger human test. Phase 3 success can lead to market availability.

The FDA regulations for safety and efficacy testing are rigid and stringent. Every company trying to get drug approval is required to follow a similar path; some make it, but most don’t.

What makes Altheus such a standout?

The company’s founder created a unique solution to a debilitating condition. OU agreed to license the technology. The founder connected with senior entrepreneurs, who had prior success in biotechnology startups, and an expert in working with the FDA.

Moving through Phase 2 testing, the firm visited the clinical trial sites to interact personally with doctors and patients and to provide support to the laborious process of recording and gathering clinical data.

As the company met commercialization milestones, Altheus’ public and private sector investors stayed loyal. The company raised a Series B round in February of 2012 and just closed an extension to that round in October. An investment affiliate of the Chickasaw Nation and

It’s a real victory for our state that Oklahoma investors have the appetite and the ability to carry a biotechnology company from scratch through a Phase 2 study of such magnitude.

If you ever think that Oklahoma might not be such a good fit for biotech, the example of Altheus suggests you think again.

Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at [email protected].

Did You Know? Only five in 5,000 of the drugs that begin preclinical testing ever make it to human testing. SOURCE: California Biomedical Research Association

Click here to read the story at newsok.com

 

More News

Loading...
Blog, Featured, News
12.16.24

MidAmerica and i2E Announce Award Winners

Read more
Blog, Featured, News
11.21.24

i2E & Plains Ventures Surpasses $100M Milestone in Total Investments

Read more
Blog
09.30.24

i2E Receives 2024 Excellence in Economic Development Award from IEDC

Read more
Blog
06.18.24

Bridge2 Demo Day Returns, Highlighting Promising Oklahoma Startups

Read more
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
05.13.24

Student Entrepreneurs Triumph at 20th Anniversary Entrepreneur’s Cup, Winning $158,000 in Prizes

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.24.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Jessica Kinsey

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Nathan Fountain

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Srijita Ghosh

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.18.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – MaxQ

Read more
Blog, i2E
01.30.24

i2E Celebrates Success of Inaugural Bridge2 Demo Day

Read more
Blog, i2E, News
12.18.23

i2E and MidAmerica Industrial Park announce award winners for high school entrepreneurship program

Read more
Blog, i2E
12.13.23

Entrepreneur’s Cup Marks 20 Years: Reimagined Competition and Brand – Same Entrepreneurial Spirit

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

12 N. Cheyenne Ave, Suite 112
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources
  • Funding
  • Venture Advisory

© 2025 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram Youtube

Programs

  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Events
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E